These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24058751)

  • 1. STAT signaling in the pathogenesis and treatment of myeloid malignancies.
    Bar-Natan M; Nelson EA; Xiang M; Frank DA
    JAKSTAT; 2012 Apr; 1(2):55-64. PubMed ID: 24058751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT signaling in the pathogenesis and treatment of cancer.
    Frank DA
    Mol Med; 1999 Jul; 5(7):432-56. PubMed ID: 10449805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of STATs in transcriptional control and their impact on cellular function.
    Bromberg J; Darnell JE
    Oncogene; 2000 May; 19(21):2468-73. PubMed ID: 10851045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia.
    Hayakawa F; Towatari M; Iida H; Wakao H; Kiyoi H; Naoe T; Saito H
    Br J Haematol; 1998 Jun; 101(3):521-8. PubMed ID: 9633897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts.
    Xia Z; Baer MR; Block AW; Baumann H; Wetzler M
    Cancer Res; 1998 Jul; 58(14):3173-80. PubMed ID: 9679986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
    Buettner R; Mora LB; Jove R
    Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of STATs in myeloid differentiation and leukemia.
    Coffer PJ; Koenderman L; de Groot RP
    Oncogene; 2000 May; 19(21):2511-22. PubMed ID: 10851050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation.
    Chaturvedi P; Reddy MV; Reddy EP
    Oncogene; 1998 Apr; 16(13):1749-58. PubMed ID: 9582023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies.
    Rah B; Rather RA; Bhat GR; Baba AB; Mushtaq I; Farooq M; Yousuf T; Dar SB; Parveen S; Hassan R; Mohammad F; Qassim I; Bhat A; Ali S; Zargar MH; Afroze D
    Front Pharmacol; 2022; 13():821344. PubMed ID: 35401182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT signaling in the pathogenesis and treatment of leukemias.
    Lin TS; Mahajan S; Frank DA
    Oncogene; 2000 May; 19(21):2496-504. PubMed ID: 10851048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.
    Weber-Nordt RM; Egen C; Wehinger J; Ludwig W; Gouilleux-Gruart V; Mertelsmann R; Finke J
    Blood; 1996 Aug; 88(3):809-16. PubMed ID: 8704235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH.
    Smit LS; Meyer DJ; Billestrup N; Norstedt G; Schwartz J; Carter-Su C
    Mol Endocrinol; 1996 May; 10(5):519-33. PubMed ID: 8732683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT5 and STAT5 Inhibitors in Hematological Malignancies.
    Tolomeo M; Meli M; Grimaudo S
    Anticancer Agents Med Chem; 2019; 19(17):2036-2046. PubMed ID: 31490767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes.
    Tian SS; Tapley P; Sincich C; Stein RB; Rosen J; Lamb P
    Blood; 1996 Dec; 88(12):4435-44. PubMed ID: 8977235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
    Venugopal S; Bar-Natan M; Mascarenhas JO
    Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential binding activity of the transcription factor LIL-STAT in immature and differentiated normal and leukemic myeloid cells.
    Tuyt LM; Bregman K; Lummen C; Dokter WH; Vellenga E
    Blood; 1998 Aug; 92(4):1364-73. PubMed ID: 9694725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis.
    Silva CM
    Oncogene; 2004 Oct; 23(48):8017-23. PubMed ID: 15489919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs.
    Klampfer L
    Curr Cancer Drug Targets; 2006 Mar; 6(2):107-21. PubMed ID: 16529541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
    Ferrajoli A; Faderl S; Ravandi F; Estrov Z
    Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.